The other side of the histamine H3 receptor

Trends in Neurosciences

Volumn 37, Issue 4, 2014, Pages 191-199

  Ellenbroek, Bart A ^a   Ghiabi, Bibinaz ^b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Addiction; Basal ganglia; D1 receptor; D2 receptor; Direct pathway; Dopamine; H3 receptor; Histamine; Indirect pathway; Parkinson disease; Schizophrenia

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ADDICTION; BASAL GANGLION; BRAIN DISEASE; BRAIN FUNCTION; DRUG DEPENDENCE; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; SYNAPSE; NEUROPATHOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; TISSUE DISTRIBUTION;

ANIMALS; BASAL GANGLIA; HUMANS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE H3; SYNAPSES;

EID: 84897438188     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.02.007     Document Type: Review

References (98)

1. Dale H.H., Laidlaw P.P. The physiological action of beta-iminazolylethylamine. J. Physiol. 1910, 41:318-344.
2. Panula P., Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 2013, 14:472-487.
3. Haas H., Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. 2003, 4:121-130.
4. Arrang J.M., et al. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302:832-837.
5. Lovenberg T.W., et al. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 1999, 55:1101-1107.
6. Leurs R., et al. The histamine H-3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. 2005, 4:107-118.
7. Leurs R., et al. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol. Sci. 2011, 32:250-257.
8. Gemkow M.J., et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 2009, 14:509-515.
9. Kravitz A.V., Kreitzer A.C. Striatal mechanisms underlying movement, reinforcement, and punishment. Physiology (Bethesda) 2012, 27:167-177.
10. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
11. Balleine B.W., O'Doherty J.P. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010, 35:48-69.
12. Matamales M., et al. Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS ONE 2009, 4:e4770.
13. Kesner R.P., Churchwell J.C. An analysis of rat prefrontal cortex in mediating executive function. Neurobiol. Learn. Mem. 2011, 96:417-431.
14. Schmidt R., et al. Canceling actions involves a race between basal ganglia pathways. Nat. Neurosci. 2013, 16:1118-1124.
15. Kravitz A.V., et al. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat. Neurosci. 2012, 15:816-818.
16. Hikida T., et al. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 2010, 66:896-907.
17. Ferguson S.M., et al. Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat. Neurosci. 2011, 14:22-24.
18. Wall N.R., et al. Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 2013, 79:347-360.
19. Pollard H., et al. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993, 52:169-189.
20. Pillot C., et al. A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience 2002, 114:173-193.
21. Ryu J.H., et al. The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3-receptors following destruction of the ascending dopaminergic neurones. Br. J. Pharmacol. 1996, 118:585-592.
22. Ryu J.H., et al. Heterogenous distribution of histamine H3, dopamine D1 and dopamine D2 receptors in rat brain. Neuroreport 1994, 5:621-624.
23. Goodchild R.E., et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur. J. Neurosci. 1999, 11:449-456.
24. Gonzalez-Sepulveda M., et al. Cellular distribution of the histamine H3 receptor in the basal ganglia: functional modulation of dopamine and glutamate neurotransmission. Basal Ganglia 2013, 3:109-121.
25. Giannoni P., et al. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridine carboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J. Pharmacol. Exp. Ther. 2010, 332:164-172.
26. Galici R., et al. Jnj-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Inflamm. Res. 2011, 60:S333.
27. Alfaro-Rodriguez A., et al. Histamine H receptor activation prevents dopamine D receptor-mediated inhibition of dopamine release in the rat striatum: a microdialysis study. Neurosci. Lett. 2013, 552:5-9.
28. Ellender T.J., et al. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. J. Neurosci. 2011, 31:15340-15351.
29. Doreulee N., et al. Histamine H3 receptors depress synaptic transmission in the corticostriatal pathway. Neuropharmacology 2001, 40:106-113.
30. 3H]-γ-aminobutyric acid from striatal slices. Br. J. Pharmacol. 2001, 133:165-171.
31. Pillot C., et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci. 2002, 22:7272-7280.
32. Moreno E., et al. Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J. Biol. Chem. 2011, 286:5846-5854.
33. Ferrada C., et al. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br. J. Pharmacol. 2009, 157:64-75.
34. 3H]-γ-aminobyturic acid release from depolarization-stimulated slices of rat substantia nigra pars reticularis. Neuroscience 1997, 80:241-249.
35. Kennedy M.J., Ehlers M.D. Mechanisms and function of dendritic exocytosis. Neuron 2011, 69:856-875.
36. Ballion B., et al. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism. Neurobiol. Dis. 2009, 35:376-384.
37. Horstink M., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society - European Section. Part I: early (uncomplicated) Parkinson's disease. Eur. J. Neurol. 2006, 13:1170-1185.
38. Shan L., et al. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol. Aging 2012, 33:e1488.e1-e1488.e13.
39. Buck K., Ferger B. L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov. Today 2010, 15:867-875.
40. Fiorentini C., et al. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in L-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. Neurobiol. Dis. 2013, 54:339-348.
41. Gomez-Ramirez J., et al. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2006, 21:839-846.
42. Heckers S., et al. Structure of the psychotic disorders classification in DSM-5. Schizophr. Res. 2013, 150:11-14.
43. Howes O.D., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 2012, 69:776-786.
44. Kegeles L.S., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 2010, 67:231-239.
45. Egerton A., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74:106-112.
46. Voorn P., et al. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 2004, 27:468-474.
47. Ellenbroek B.A. Psychopharmacological treatment of schizophrenia: what do we have and what could we get?. Neuropharmacology 2012, 62:1371-1380.
48. Moghaddam B., Krystal J.H. Capturing the angel in 'angel dust': twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 2012, 38:942-949.
49. Akhtar M., et al. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundam. Clin. Pharmacol. 2006, 20:373-378.
50. Motawaj M., Arrang J.M. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur. J. Neurosci. 2011, 33:1197-1204.
51. Mahmood D., et al. Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models. Pharmacol. Rep. 2012, 64:191-204.
52. Southam E., et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology (Berl.) 2009, 201:483-494.
53. Brabant C., et al. Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology (Berl.) 2009, 202:673-687.
54. Geyer M.A., et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenic patients: a decade in review. Psychopharmacology (Berl.) 2001, 156:117-154.
55. Bardgett M.E., et al. Effects of the H3 antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats. Psychopharmacology (Berl.) 2009, 205:589-597.
56. Burban A., et al. Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl.) 2010, 210:591-604.
57. Flood D.G., et al. Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse. Psychopharmacology (Berl.) 2011, 215:441-454.
58. Ellenbroek B.A. Schizophrenia. Encyclopedia of Behavioral Neuroscience 2010, 188-195. Academic Press. G.F. Koob (Ed.).
59. Egan M.F., et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr. Res. 2013, 146:224-230.
60. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004, 5:483-494.
61. Pelloux Y., et al. Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats. Neuropsychopharmacology 2012, 37:2505-2514.
62. Jonkman S., et al. Differential roles of the dorsolateral and midlateral striatum in punished cocaine seeking. J. Neurosci. 2012, 32:4645-4650.
63. Jonkman S., et al. Drug intake is sufficient, but conditioning is not necessary for the emergence of compulsive cocaine seeking after extended self-administration. Neuropsychopharmacology 2012, 37:1612-1619.
64. Everitt B.J., Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 2005, 8:1481-1489.
65. Belin D., et al. Addiction: failure of control over maladaptive incentive habits. Curr. Opin. Neurobiol. 2013, 23:564-572.
66. Everitt B.J., Robbins T.W. From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci. Biobehav. Rev. 2013, 37:1946-1954.
67. Cools A.R. The relevance of feedforward loops. Behav. Brain Sci. 1987, 10:210.
68. Ikeda H., et al. Accumbal core: essential link in feed-forward spiraling striato-nigro-striatal in series connected loop. Neuroscience 2013, 252C:60-67.
69. Ikeda H., et al. Spiraling dopaminergic circuitry from the ventral striatum to dorsal striatum is an effective feed-forward loop. Neuroscience 2013, 241:126-134.
70. Willuhn I., et al. Hierarchical recruitment of phasic dopamine signaling in the striatum during the progression of cocaine use. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20703-20708.
71. Ellenbroek B.A. Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction. Br. J. Pharmacol. 2013, 170:46-57.
72. Nuutinen S., et al. Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 2011, 60:1193-1199.
73. Nuutinen S., et al. Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology 2011, 36:2030-2040.
74. Brabant C., et al. The H3 antagonist thioperamide reveals conditioned preference for a context associated with an inactive small dose of cocaine in C57BL/6J mice. Behav. Brain Res. 2005, 160:161-168.
75. Munzar P., et al. Histamine H3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology 2004, 29:705-717.
76. Badiani A., et al. Opiate versus psychostimulant addiction: the differences do matter. Nat. Rev. Neurosci. 2011, 12:685-700.
77. Lucas G., et al. Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function. Eur. J. Neurosci. 2001, 13:889-898.
78. Porras G., et al. Central serotonin4 receptors selectively regulate the impulse-dependent exocytosis of dopamine in the rat striatum: in vivo studies with morphine, amphetamine and cocaine. Neuropharmacology 2002, 43:1099-1109.
79. Porras G., et al. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002, 26:311-324.
80. Uguen M., et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil. Br. J. Pharmacol. 2013, 169:632-644.
81. Hudzik T.J., et al. Assessment of the abuse liability of ABT-288, a novel histamine H3 receptor antagonist. Psychopharmacology (Berl.) 2013, 228:187-197.
82. van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr. Drug Abuse Rev. 2012, 5:3-31.
83. Gbahou F., et al. The histamine autoreceptor is a short isoform of the H3 receptor. Br. J. Pharmacol. 2012, 166:1860-1871.
84. Ferrada C., et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008, 55:190-197.
85. Perreault M.L., et al. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J. Biol. Chem. 2010, 285:36625-36634.
86. Lammel S., et al. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 2011, 70:855-862.
87. Graybiel A.M., Ragsdale C.W. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:5723-5726.
88. Crittenden J.R., Graybiel A.M. Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front. Neuroanat. 2011, 5:59.
89. Mailly P., et al. The rat prefrontostriatal system analyzed in 3D: evidence for multiple interacting functional units. J. Neurosci. 2013, 33:5718-5727.
90. Gruber A.J., McDonald R.J. Context, emotion, and the strategic pursuit of goals: interactions among multiple brain systems controlling motivated behavior. Front. Behav. Neurosci. 2012, 6:50.
91. Bradfield L.A., et al. The thalamostriatal pathway and cholinergic control of goal-directed action: interlacing new with existing learning in the striatum. Neuron 2013, 79:153-166.
92. Shiflett M.W., et al. Acquisition and performance of goal-directed instrumental actions depends on ERK signaling in distinct regions of dorsal striatum in rats. J. Neurosci. 2010, 30:2951-2959.
93. Milton A.L., Everitt B.J. The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. Neurosci. Biobehav. Rev. 2012, 36:1119-1139.
94. Nuutinen S., et al. Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology (Berl.) 2010, 208:75-86.
95. Bahi A., et al. Influence of the novel histamine H3 receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice. Psychopharmacology (Berl.) 2013, 228:85-95.
96. Lintunen M., et al. Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H3 receptor mechanisms. FASEB J. 2001, 15:1074-1076.
97. Perez-Garcia C., et al. Effects of thioperamide on the conditioned place preference and the physical dependence induced by morphine in the rat. Pharmacol. Rev. Commun. 1999, 10:291-298.
98. Okuda T., et al. Methamphetamine- and 3,4-methylenedioxymethamphetamine-induced behavioral changes in histamine H3-receptor knockout mice. J. Pharmacol. Sci. 2009, 111:167-174.